- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04394000
Impact of an Intensified Thromboprofylaxis Protocol in COVID-19
Impact of Implementation of an Intensified Thromboprofylaxis Protocol in in Critically Ill ICU Patients With COVID-19: a Longitudinal Controlled Before-after Study
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Background Patients admitted to the Intensive Care Unit (ICU) are known to be at risk for thrombo-embolic events. Virchow's triad describes the major risk factors in three categories: venous stasis, vessel injury and activation of blood coagulation. A prolonged mechanical ventilation together with the hemodynamic effects of this ventilation with a high positive and expiratory pressure (PEEP), the presence of central venous catheters, the immobilization of these patients and the presence of obesity or other comorbidities can attribute to the occurrence of a deep venous thrombosis (DVT) in patients admitted at ICU. The incidence of DVT during ICU stay has been reported between 5 and 15%.
On the 13th of March, the first COVID-19 patient was admitted at the ICU at the Jessa Hospital. Within a few days, the admissions at our COVID-19 unit grew exponential. In these difficult time, research concerning COVID-19 has been performed indicating the COVID-19 virus induces a hyper-inflammatory state. It has been suggested that systemic inflammation induces endothelial injury. This will activate the coagulation cascade and impair fibrinolysis with disruption of endothelial barrier, and loss of physiologic antithrombotic factors which may elevated the risk for DVTs significantly. Up to now, there is still no causal treatment for COVID-19. The current management of COVID-19 is mainly supportive i.e. a prolonged inflammatory status and a prolonged risk for VTE.
We have shown in a previous cross sectional study that the prevalence of deep venous thrombosis (DVT) in critically ill ICU patients with COVID-19 treated with a prophylactic dose of low molecular weight heparin (LMWH) is more than 60% (submitted manuscript). Consequently, the risk of VTE complications in this patient group is very high. In the light of these findings, an intensified thromboprofylaxis protocol was applied in critically ill ICU patients with COVID-19 at our ICU units since 31st of March 2020.
Aim The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.
Design This is a retrospective, longitudinal, before-after controlled study investigating the mortality, the incidence of DVT and the incidence of kidney and liver failure in COVID-19 patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol.
Outcome measures The primary endpoint of this retrospective study is to investigate the mortality in critically ill ICU patients before and after the implementation of the intensified thromboprofylaxis protocol in our hospital.
Secondary endpoints are the incidence of DVTs with the number and locations of these thromboses, the incidence of kidney failure and the incidence of liver failure in COVID-19 patients admitted to the ICU before and after the implementation of the thromboprofylaxis protocol.
Additional data collection
Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:
- Demographics: i.e age, gender, BMI, Apache II score (to predict mortality)
- Comorbidities: smoking, obesity, hypertension, diabetes, cardiovascular disease, respiratory disease, malignancies, renal failure (AKI), liver failure, gastrointestinal disease, neurological conditions, mental state, other
- Symptoms at the time of admission to ICU: i.e fever, body temperature, dyspnoea, headache, diarrhea etc…
- Laboratory results of all standard parameters measured
- Treatment: antiviral agents, antibiotics, etc…
- Complications: shock, heart failure, sepsis, stroke, etc…
- Ventilation: method, PEEP, FiO2, P/F ratio ..
- SOFA score (Sequential Organ Failure Assessment)
- Radiological findings: pneumonia, ground-glass opacity..
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
-
Hasselt, Belgie, 3500
- Jessa Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.
Exclusion Criteria:
- Patients younger than 18 years old.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Before or control group
All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
|
This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
|
|
After or intervention group
On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented.
This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
|
This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
2 week mortality
Časové okno: 2 weeks after admission at ICU
|
mortality was assessed in all COVID 19 patients admitted to the ICU
|
2 weeks after admission at ICU
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
incidence of venous thromboembolism
Časové okno: during ICU stay up till 3th of May 2020
|
the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
1 week mortality
Časové okno: 1 week after admission at ICU
|
mortality was assessed in all COVID 19 patients admitted to the ICU
|
1 week after admission at ICU
|
|
3 week mortality
Časové okno: 3 weeks after admission at ICU
|
mortality was assessed in all COVID 19 patients admitted to the ICU
|
3 weeks after admission at ICU
|
|
1 month mortality
Časové okno: 1 month after admission at ICU
|
mortality was assessed in all COVID 19 patients admitted to the ICU
|
1 month after admission at ICU
|
|
incidence of kidney failure
Časové okno: during ICU stay up till 3th of May 2020
|
incidence of acute kidney failure in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
incidence of continuous renal replacement therapy (CRRT)
Časové okno: during ICU stay up till 3th of May 2020
|
incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
lowest PaO2/FiO2 (P/F) ratio
Časové okno: during ICU stay up till 3th of May 2020
|
evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
highest Sequential Organ Failure Assessment (SOFA) score
Časové okno: during ICU stay up till 3th of May 2020
|
evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
length of stay
Časové okno: during ICU and hospital stay up till 3th of May 2020
|
evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU
|
during ICU and hospital stay up till 3th of May 2020
|
|
highest bilirubin
Časové okno: during ICU stay up till 3th of May 2020
|
evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
highest ( AST
Časové okno: during ICU stay up till 3th of May 2020
|
evaluation of the highest AST level in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
|
highest Aspartaat-Amino-Transferase (ALT)
Časové okno: during ICU stay up till 3th of May 2020
|
evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU
|
during ICU stay up till 3th of May 2020
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- Jessa_20.48
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .